
Sign up to save your podcasts
Or


Brad Loncar, Head of Loncar Investments, joins us in studio to spotlight the index behind the Loncar Cancer Immunotherapy ETF (CNCR) and discuss the innovation occurring in cancer treatment. Nate and Conor also explain why ETFs can be an excellent way to access the biotech space in general.
By Nate Geraci4.5
6464 ratings
Brad Loncar, Head of Loncar Investments, joins us in studio to spotlight the index behind the Loncar Cancer Immunotherapy ETF (CNCR) and discuss the innovation occurring in cancer treatment. Nate and Conor also explain why ETFs can be an excellent way to access the biotech space in general.

521 Listeners

2,201 Listeners

1,967 Listeners

948 Listeners

105 Listeners

284 Listeners

797 Listeners

2,035 Listeners

198 Listeners

2,149 Listeners

930 Listeners

85 Listeners

90 Listeners

111 Listeners

825 Listeners